213 related articles for article (PubMed ID: 37296369)
1. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
Meunier A; Longworth L; Gomes M; Ramagopalan S; Garrison LP; Popat S
Pharmacoeconomics; 2023 Aug; 41(8):1011-1025. PubMed ID: 37296369
[TBL] [Abstract][Full Text] [Related]
2. An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective.
Meunier A; Opeifa O; Longworth L; Cox O; Bührer C; Durand-Zaleski I; Kelly SP; Gale RP
Eye (Lond); 2024 Mar; ():. PubMed ID: 38555401
[TBL] [Abstract][Full Text] [Related]
3. Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.
Ward T; Mujica-Mota RE; Spencer AE; Medina-Lara A
Pharmacoeconomics; 2022 Jan; 40(1):45-64. PubMed ID: 34713423
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis.
Kowal S; Ng CD; Schuldt R; Sheinson D; Cookson R
Value Health; 2023 Feb; 26(2):216-225. PubMed ID: 36192293
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
6. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.
Goshua G; Calhoun C; Ito S; James LP; Luviano A; Krishnamurti L; Pandya A
Ann Intern Med; 2023 Jun; 176(6):779-787. PubMed ID: 37247420
[TBL] [Abstract][Full Text] [Related]
7. Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia.
Dawkins BR; Mirelman AJ; Asaria M; Johansson KA; Cookson RA
Health Policy Plan; 2018 Apr; 33(3):456-463. PubMed ID: 29309581
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
9. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan.
Leung JH; Chang CW; Chan AL; Lang HC
Future Oncol; 2022 Mar; 18(7):859-870. PubMed ID: 35105168
[TBL] [Abstract][Full Text] [Related]
14. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
16. Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges.
Meunier A; Longworth L; Kowal S; Ramagopalan S; Love-Koh J; Griffin S
Value Health; 2023 Jan; 26(1):60-63. PubMed ID: 35941004
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
19. The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis.
Jansen JP; Ragavan MV; Chen C; Douglas MP; Phillips KA
Value Health; 2023 Dec; 26(12):1697-1710. PubMed ID: 37741446
[TBL] [Abstract][Full Text] [Related]
20. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]